scholarly journals Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease

2009 ◽  
Vol 15 (1) ◽  
pp. 63-68 ◽  
Author(s):  
Folashade Adebisi Jose ◽  
Elizabeth A. Garnett ◽  
Eric Vittinghoff ◽  
George D. Ferry ◽  
Harland S. Winter ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Extraintestinal Manifestations ◽  
Inflammatory Bowel

P0699 EPIDEMIOLOGICAL FEATURES OF EXTRAINTESTINAL MANIFESTATIONS IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE

2004 ◽  
Vol 39 (Supplement 1) ◽  
pp. S323
Author(s):  
M. B. Heyman ◽  
G. D. Ferry ◽  
B. S. Kirschner ◽  
T. Clemons ◽  
B. D. Gold ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Extraintestinal Manifestations ◽  
Epidemiological Features ◽  
Inflammatory Bowel

Su1275 Prevalence of Extraintestinal Manifestations in Pediatric Patients With Inflammatory Bowel Disease: Results From the Swiss IBD Cohort Study

2015 ◽  
Vol 148 (4) ◽  
pp. S-458-S-459
Author(s):  
Stephan R. Vavricka ◽  
Roman Rechner ◽  
Nicolas Fournier ◽  
Gerhard Rogler ◽  
Pierre F. Michetti ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Cohort Study ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Extraintestinal Manifestations ◽  
Inflammatory Bowel

Nutritional status and food intake in pediatric patients with inflammatory bowel disease at diagnosis significantly differs from healthy controls

2019 ◽  
Vol 178 (10) ◽  
pp. 1519-1527 ◽  
Author(s):  
Sara Sila ◽  
Ivana Trivić ◽  
Ana Močić Pavić ◽  
Tena Niseteo ◽  
Sanja Kolaček ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Food Intake ◽  
Nutritional Status ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Healthy Controls ◽  
Inflammatory Bowel

scholarly journals Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease—A Single Center Case–Control Study

2021 ◽  
Vol 10 (14) ◽  
pp. 3177
Author(s):  
Edyta Szymanska ◽  
Maciej Dadalski ◽  
Joanna Sieczkowska-Golub ◽  
Dorota Jarzebicka ◽  
Monika Meglicka ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Case Control Study ◽  
Case Control ◽  
Chi Square ◽  
Infusion Reactions ◽  
Inflammatory Bowel ◽  
The Difference ◽  
Control Study

Background: Infusion reactions (IRs) are the most common adverse events (AEs) of infliximab (IFX) treatment in patients with inflammatory bowel disease (IBD). Prophylactic premedication (PM) with corticosteroids or antihistamines prior to IFX infusions has been used in clinical practice, but its efficacy is not known. The aim of this study was to assess the influence of steroid PM on IR incidence in pediatric patients with IBD receiving IFX. Methods: We performed a case–control study that included pediatric patients with IBD receiving IFX. Patients were divided into four subgroups according to the agent and PM they received: Remicade (original drug) + PM, and two biosimilars—Reshma +/− PM, and Flixabi—PM. At our site, until 2018, PM with steroids was used as a part of standard IFX infusion (PM+); however, since then, this method has no longer been administered (PM−). IRs were divided into mild/severe reactions. Differences between subgroups were assessed with the appropriate chi-square test. Multivariate logistic regression was used to assess associations between PM and IR incidence, correcting for co-medication usage. Results: There were 105 children (55 PM+, 44 male, mean age 15 years) included in the study who received 1276 infusions. There was no difference between the PM+ and PM− subgroups, either in incidence of IR (18.2% vs. 16.0% of patients, p > 0.05) or in percentage of infusions followed by IR (2.02% vs. 1.02% of infusions, p > 0.5). The OR of developing IR when using PM was 0.34, and the difference in IRs ratio in PM+ and PM− patients was not statistically significant (95% CI, 0.034–1.9). There were 11/18 (61.1%) severe IRs (anaphylactic shock) reported in all patients (both PM+ and PM−). Conclusion: At our site, the incidence of IR was low, and PM did not decrease the incidence of IR in pediatric patients with IBD receiving IFX. These results indicate that PM with steroids should not be a standard part of IFX infusion to prevent IR.

scholarly journals A186 OLDER AGE IS ASSOCIATED WITH INCREASED EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE

2021 ◽  
Vol 4 (Supplement_1) ◽  
pp. 201-202
Author(s):  
Z Chattha ◽  
R Chattha ◽  
S Reza ◽  
M Moradshahi ◽  
M Fadida ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Regression Analysis ◽  
Bowel Disease ◽  
Multivariate Regression Analysis ◽  
Older Age ◽  
Extraintestinal Manifestations ◽  
Forward Selection ◽  
Increased Risk ◽  
Inflammatory Bowel

Abstract Background The relationship between older age and extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) remains unknown. Aims This study aims to determine whether older age is associated with increased risk of EIMs in IBD patients. Methods This was a retrospective study of IBD patients seen at the McMaster University Medical Centre, in Hamilton, ON, Canada from 2012–2020. Patients were identified to have the primary outcome of interest if their gastroenterologist documented the presence of any EIM either during the baseline assessment or during the period of follow up. The independent variable, age at start of follow-up, was dichotomized into two categories age >=40 vs. <40.Prior knowledge in combination with forward selection was used to develop a logistic regression model. The variables utilized for the forward selection model included gender, disease duration, and current biologic use. Results A total of 995 IBD patients (625 with CD) were considered for the regression analysis, all for whom the EIM status was recorded. Out of the 995 patients, 270 patients reported at least one EIM – 99 with arthritis/arthralgia, 79 with dermatologic manifestations, 16 with ophthalmic manifestations, 30 with liver manifestations, and 116 with other EIMs. A univariate regression analysis foundincreased odds of EIMs in older patientsas compared to younger patients (odds ratio (OR) 1.41 (95% CI, 1.05 – 1.89)). In the multivariate regression analysis, current biologic use was found to have a significant relationship with odds of having EIMs (OR 1.49; 95% CI, 1.06 – 2.09). After adjustment for biologic use, patients aged 40 or over had 1.46 times higher odds of having EIMs (95% CI 1.03 – 2.05). A sub-analysis of individual EIM categoriesdid not show a significant association with older age. Conclusions Older age is associated with increased risk of EIMs in IBD patients. Patients with EIMs were also more likely to be treated with biological therapies. Clinicians should inquire about the presence of EIMs in older IBD patients. Funding Agencies None

Diagnostic Medical Radiation in Pediatric Patients With Inflammatory Bowel Disease

2011 ◽  
Vol 53 (5) ◽  
pp. 502-506 ◽  
Author(s):  
Jeannie S. Huang ◽  
Allison Tobin ◽  
Lee Harvey ◽  
Thomas R. Nelson
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Medical Radiation ◽  
Inflammatory Bowel

scholarly journals Infliximab Concentrations During Induction Are Predictive for Endoscopic Remission in Pediatric Patients With Inflammatory Bowel Disease Under Combination Therapy

2021 ◽  
Author(s):  
Karen van Hoeve ◽  
Nasim Sadat Seyed Tabib ◽  
Erwin Dreesen ◽  
Sophie Tops ◽  
Ilse Hoffman ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Combination Therapy ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Endoscopic Remission ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document